The Call Came From Inside: Epstein–Barr virus and the biology of persistence
- Heather McSharry, PhD
- 10 hours ago
- 14 min read
Summary
Epstein–Barr virus is one of the most common infections in the world—by adulthood, nearly 95% of people carry it. Most remember it, if at all, as “just mono.” A brief illness. A recovery. The end of the story.
Except it isn’t.
EBV doesn’t leave. It stays—inside the very immune cells responsible for remembering infection. For most people, it exists quietly, held in check by the immune system. But under certain conditions, that balance can shift, linking this common virus to cancers, autoimmune disease, and long-term biological change.
In this episode, we explore what it means to live with a lifelong infection: how Epstein–Barr virus enters the body, how it hides, how it persists, and why a virus most people never think about may be shaping human health in ways we’re only beginning to understand.
Listen here or scroll down to read full episode.
Also available on all major podcast platforms
Full Episode
In-text citations linking to papers behind paywalls, are provided as PDFs in the citation list after my signature at the end of the post.
There’s a virus you probably already have. Not a rare one. Not something you were warned about. A common one. Quiet. Persistent. Easy to miss. By adulthood, about 9 out of 10 people have been infected. Most don’t remember when. Some remember it as “just mono.” A sore throat. A few weeks of exhaustion. Then it’s over. Except it isn’t. Because Epstein–Barr virus doesn’t leave. It stays.
It stays in your B cells. In the background of your life. And most of the time, that doesn’t matter. Until it does—when a virus that’s been silent for years becomes part of something much more serious. Today, we’re not talking about an outbreak. We’re talking about what it means to carry an infection for the rest of your life— and why one of the most common viruses on Earth might also be one of the most underestimated. This is The Call Came From Inside: Epstein–Barr virus and the biology of persistence
Most of the time, when we think about infection, we think about something that happens—and then ends. You get sick. You recover. Maybe you remember it. Maybe you don’t. But either way, it’s over.
That’s the story we’re used to: infection as an event. Something with a beginning—and an end. But not all pathogens follow that pattern. Some don’t leave. And once a virus stays, it stops being something that happened to you—and becomes something you live with. And that’s a harder thing to think about. It means there isn’t a clear ending. There isn’t a moment where you can say, I’m done with this. There’s just… a shift. From infection to coexistence.
We actually know this pattern pretty well in biology. There are entire families of viruses built around it: herpesviruses, varicella-zoster, cytomegalovirus. Pathogens that infect once—and then remain for life. But even knowing that, we tend to treat those infections as if they’re still events. You had chickenpox. You had mono. Past tense.
Biologically, that’s not quite true. For these viruses, the acute illness—the fever, the rash, the exhaustion—is just the visible part of the interaction. The part we notice. What happens after that is the part we tend to ignore. And that's a mistake.
And Epstein–Barr virus is one of the clearest examples of this. Not because it’s rare—but because it’s almost universal.
A Virus Built to Stay
To understand that a little better, let's talk more about the virus itself. Epstein–Barr virus, or EBV, is an enveloped icosahedral virus. That means the virus particle is formed by 20 equilateral triangular faces and 12 vertices. They use 162 subunits called capsomeres to form their stable, nearly spherical capsid that protects their viral genome...and each virus particle is approximate 150nm in diameter. The EBV viral genome consists of a linear double-stranded DNA molecule of 172 kbp, which encodes approximately 100 viral proteins. So it's a DNA virus.
EBV belongs to a family that’s built exactly for staying with us... the Herpesviridae family...the same group that includes herpes simplex virus, which causes cold sores, and varicella-zoster virus, which causes chickenpox and later shingles. Specifically, it is in the Gammaherpesvirinae subfamily and is classified as human herpesvirus 4 (HHV-4). These are viruses that don’t give us clean endings. They infect once—and then they settle in for the long haul.
And that persistence isn’t just a general trait—it’s engineered into how these viruses enter cells, move through the body, and interact with the immune system.
So Epstein–Barr virus doesn’t spread in a way that feels dramatic. It moves through something much more ordinary: saliva. Kissing is the example people remember, but it’s just as easily shared through quieter moments—like a drink passed across a table, utensils shared without thinking, the constant exchange of objects in childhood. But under that simplicity, the biology is doing something more deliberate.
The virus first encounters epithelial cells—the cells lining the surface of the mouth and airway—in the tonsils. There, EBV uses a set of surface proteins to attach and fuse with these cells, allowing it to replicate locally and produce more virus. But epithelial cells are not its final destination.
Very quickly, EBV shifts targets. It moves into B cells—cells of the immune system—and it does this using a highly specific mechanism. On its surface, the virus carries a protein called gp350, which acts like a docking tool. This protein binds to a receptor on B cells called CD21—a molecule those cells normally use as part of their immune function.
That interaction pulls the virus into close contact with the cell. Then a second viral protein, called gp42, engages with HLA class II molecules on the B cell surface—structures normally used to present antigens to the immune system. This second step triggers fusion between the viral membrane and the cell, allowing the virus to deliver its genetic material inside.
Two steps. Two different host molecules. One outcome: the virus gains entry directly into the immune system. That specificity is key. Because EBV isn’t just infecting any cell it happens to encounter. It’s targeting cells that are already built to survive, circulate, and persist.
Once inside a B cell, the virus travels to the nucleus—the control center of the cell—and its DNA forms a circular structure, called an episome, that sits alongside the cell’s own genome rather than integrating into it under typical conditions. It doesn’t immediately destroy the cell. It doesn’t immediately produce large amounts of virus.
Instead, it changes strategy. It begins expressing a carefully selected set of genes—just enough to take control of the cell’s behavior without drawing too much attention. This allows EBV to expand the number of infected cells early on. But that’s only the first phase.
As the immune system responds and begins to recognize infected cells, the virus shifts again. It reduces its visibility. It turns off most of its genes and enters a quieter state—what we call latency.
Now, instead of driving rapid growth, it focuses on persistence. It steers infected B cells into becoming memory B cells—the long-lived cells that circulate through the body for years, sometimes decades. These are cells that are naturally maintained by the immune system. They’re not eliminated. They’re preserved. By embedding itself in these cells, EBV effectively places itself inside the body’s own long-term storage system.
This is the key shift.
EBV doesn’t just evade the immune system by hiding. It adapts to the rhythms of the immune system itself—expanding when it can, retreating when it must.
How It Stays: Latency
So that means, like all herpesviruses, Epstein–Barr virus doesn’t simply disappear after infection. But what makes EBV different is how precisely it controls that latent state.
EBV doesn’t rely on a single form of latency. It has multiple distinct patterns of gene expression—what scientists call latency programs—and it can shift between them depending on context .
At one extreme, the virus is almost completely silent. It expresses little more than small noncoding RNAs and a single maintenance protein. In this state, infected cells are extremely difficult for the immune system to recognize. At the other extreme, the virus expresses a broader set of genes—proteins that actively reshape the behavior of the B cell. Some mimic normal immune signals, pushing the cell to grow, divide, and survive. This can expand the population of infected cells, particularly early in infection or when immune control is weaker. Between those extremes are intermediate states—where the virus reveals just enough to maintain control, but not enough to fully expose itself.
And that flexibility is what makes Epstein–Barr virus so difficult to eliminate. Because the immune system isn’t dealing with a fixed target. It’s dealing with something that can continuously adjust its visibility—becoming more active when it needs to expand, and more silent when it needs to hide.
It Never Fully Stops
So even when EBV is quiet, it’s not gone. Inside infected B cells, the virus can sit for years in that latent state—largely invisible, producing little to no new virus. But that silence isn’t permanent. Every so often, some of those cells switch back. They reactivate.
This shift is not random. It’s often tied to normal biology—when B cells become activated as part of an immune response, or when they receive signals to divide. Under those conditions, the virus responds to changes in the cell’s state and transitions out of latency.
When that happens, EBV turns its genes back on in a specific sequence. Early genes prepare the cell for viral replication. Then the machinery for copying viral DNA is activated. Finally, structural proteins are produced, assembling new viral particles. The cell becomes a factory. New virus is released, which can go on to infect additional cells in the body—or be shed into saliva and transmitted to someone else. And this can happen without obvious symptoms.
Most reactivation events are controlled quickly by the immune system. They occur at a low level, below the threshold of what you would feel as illness. But they are enough to maintain the virus within the body—and to allow it to continue spreading between people. So carrying Epstein–Barr virus isn’t a static condition. It’s a dynamic one. A continuous cycle of latency and reactivation—suppression and release—playing out over time, mostly out of sight.
In most people, this cycle is tightly controlled. The immune system—particularly cytotoxic T cells—constantly surveys the body for signs of infected cells. When EBV begins to reactivate and express more of its proteins, those cells become visible. Viral fragments are displayed on the surface of infected cells, and T cells recognize them as abnormal.
When that happens, the infected cells are eliminated. This ongoing surveillance is what keeps EBV in check. But the relationship isn’t one-sided. Because the virus has evolved alongside the immune system—and it has developed ways to shape that interaction. Some viral proteins actively interfere with how infected cells display viral fragments on their surface, making them harder for the immune system to “see.” Others mimic normal cellular signals, allowing infected cells to blend in with healthy ones.
So the immune system is not simply clearing the virus. It’s engaged in a constant negotiation with it. And in most people, that balance holds. But not always. In situations where immune control is weakened—such as during immunosuppression—reactivation can become more extensive. Infected cells can expand more freely. And the consequences become much more visible.
There’s another layer to this interaction as well—one that is still being actively studied.
In some cases, the immune response to EBV may not stay perfectly targeted. One possible mechanism is molecular mimicry, where certain viral proteins resemble human proteins closely enough that the immune system struggles to distinguish between them. When T cells or antibodies are activated against the virus, they may, in some cases, also react to similar structures in the body.
This doesn’t mean Epstein–Barr virus directly causes autoimmune diseases. But it may contribute to them—as one factor among many—by increasing the likelihood that the immune system’s precision slips. And that possibility reinforces the importance of what we talked about. EBV doesn't just hide from the immune system. It engages with it.
When Coexistence Breaks Down
OK, so usually, the immune system keeps EBV-infected cells in check. But if the immune system is weakened—by HIV infection, by organ transplantation, or by medications that suppress immune function—the controls that normally limit EBV begin to loosen. The T cells that patrol for infected cells become less effective. Signals that would normally trigger elimination are missed. And that changes the behavior of the virus.
Cells that would have been destroyed are now allowed to survive. Cells that would have been kept in a resting state can begin to grow.
In some cases, this leads to what’s called a lymphoproliferative disorder—an abnormal expansion of infected immune cells that can evolve into cancer. This is why EBV is linked to a range of malignancies, including Hodgkin lymphoma, Burkitt lymphoma, and nasopharyngeal carcinoma, as well as certain lymphomas that arise specifically in immunocompromised individuals.
Globally, EBV is associated with hundreds of thousands of cancer cases each year. But even here, the story isn’t simple. Because not all infections behave the same way. Most people carry EBV for life and never develop cancer. Which raises a deeper question: If the virus is so common, why are its most serious consequences relatively rare?
It’s Not Just the Virus
Part of the answer lies in something we’re only beginning to fully understand. The risk of EBV-related disease depends not only on the virus—but on the interaction between the virus and the host. Not all Epstein–Barr viruses are identical. Different strains carry small genetic differences that can affect how viral proteins are expressed, how strongly they interact with the immune system, and how effectively they drive cell growth.
At the same time, not all immune systems respond in the same way. Human immune genes—particularly those involved in antigen presentation, like HLA molecules—vary from person to person. These molecules determine how viral fragments are displayed to T cells, and therefore how effectively infected cells are recognized and eliminated. What recent research has shown is that these two layers—viral variation and human genetic variation—can interact.
Certain combinations of viral strain and host immune genotype can significantly increase the risk of disease. In these cases, the virus may be less visible to the immune system, or the immune response may be less effective at targeting it. The result is not just a stronger infection—but a different kind of interaction altogether. One where the balance between viral persistence and immune control is shifted. Which means disease isn’t determined by the virus—or the host—alone—but by the interactions between them. And that idea—that risk emerges from the relationship, not just the components—is becoming central to how we understand not just EBV, but many infectious diseases.
Where We Are Now
Despite how common EBV is, we still don’t fully control it. There’s no approved vaccine. No treatment that eliminates it from the body. And that’s not for lack of trying. Part of the challenge is biological. EBV doesn’t just circulate in the bloodstream where drugs can easily reach it. It hides inside B cells, often in a latent state where it produces very few viral proteins. In that state, there’s almost nothing for antiviral drugs to target. Even when it does reactivate, it does so briefly and often at low levels—making it difficult to interrupt consistently.
So most current treatments don’t target the virus directly. Instead, they target the consequences. In EBV-related cancers, therapies focus on killing rapidly dividing cells or restoring immune control. In transplant patients, clinicians monitor viral load and adjust immunosuppression to keep the virus in check. But that’s management—not prevention.
That may be starting to change. One of the most promising strategies focuses on a very specific moment in the viral life cycle: entry into cells.
As we’ve seen, EBV relies on precise interactions between its surface proteins and receptors on human cells—proteins like gp350, which binds to B cells, and gp42, which helps trigger fusion and entry. If those interactions can be blocked, the virus can’t establish infection in the first place.
Recent research has begun to make that idea more tangible. In a 2026 study, scientists used genetically engineered mice—designed to produce human-like antibodies—to generate antibodies that specifically target these entry proteins. Some of these antibodies were able to block the virus from attaching to and entering B cells, effectively shutting down the infection step that leads to lifelong virus infection.
Even more striking, when one of these antibodies was tested in a model with human immune cells, it completely prevented detectable B cell infection following viral exposure. That’s something researchers have struggled to achieve for years. These antibodies work by physically interfering with the virus’s ability to bind its receptors—blocking gp350 from binding CD21 and preventing gp42 from engaging HLA class II—key steps required for EBV to enter B cells. Importantly, this effect is specific to the pathway EBV uses to infect B cells—it does not necessarily block the virus’s ability to infect epithelial cells.
This doesn’t eliminate EBV from someone who is already infected. But it suggests something important: preventing the establishment of infection in B cells may be possible. And that opens the door to new approaches. Like vaccines that train the immune system to produce similar antibodies. Or preventive therapies for high-risk patients, like transplant recipients. Or even strategies to limit viral spread at the population level. Now, preventing EBV’s entry into B cells in a controlled non-human animal experiment is not the same as blocking that process outside of a lab in a human, where timing, viral dose, and immune responses all vary. Even so, vaccines based on these findings could still provide meaningful protection. Reducing the virus’s ability to infect B cells—or limiting the number of cells it successfully enters—could significantly reduce the establishment of long-term persistence and, with it, the risk of downstream disease. It’s important to recognize that the most relevant measure of success for a vaccine is not complete prevention of infection, but its ability to alter these outcomes.
Either way, we’re not there yet. But for the first time in a long time, there’s a clearer path forward—not just for managing EBV, but for interrupting it. But, for now, EBV isn’t something we cure. It’s something we manage—and coexist with.
There’s a virus you probably already have. One that didn’t announce itself. You may not even remember it. For most people, it passed quietly—if it was noticed at all. And then it seemed to be over. But now you know—that wasn’t the end of the story.
Because Epstein–Barr virus doesn’t leave. It settles into the background. Held in check. Mostly silent. But still there. And in most lives, it stays that way. Controlled. Unremarkable. Until, in certain contexts, it isn’t. Not because the virus suddenly changes—but because the balance around it does. Which means what you’re carrying isn’t just a past infection. It’s something ongoing. Something managed. Something that, under the right conditions, can matter again. A virus that is usually quiet. Usually harmless.
And almost always overlooked.
Thanks for being here. Last week I mentioned we’d be covering Lassa virus next but I changed my mind so that will be coming later. And don't forget to sign up for my new, free weekly newsletter, Field Notes, where I continue the conversation on the episode, share things I’m paying attention to and behind-the-scenes insights. And stay tuned because next week is an Outbreak After Dark episode on the worst (and honestly, grossest) infection treatments in history. It’ll be a fun, fascinating break from the heavier timeline we’re all living through right now.
Annotated Citations
Whitley RJ. 1996. Herpesviruses. In: Baron S, editor. Medical Microbiology. 4th edition. Galveston (TX): University of Texas Medical Branch at Galveston; Chapter 68.
→ Foundational textbook overview of herpesvirus biology; useful for broad background on structure, lifecycle, and persistence strategies across the herpesvirus family.
Mathias Ackermann. 2006. Pathogenesis of gammaherpesvirus infections. Veterinary Microbiology.
→ Comparative and mechanistic review of gammaherpesviruses; helpful for understanding EBV in the context of related viruses and general persistence & pathogenesis strategies.
URL: https://www.sciencedirect.com/science/article/abs/pii/S037811350500369X?via%3Dihub Behind paywall:
Christian Münz. 2025. Epstein–Barr virus pathogenesis and emerging control strategies. Nature Reviews Microbiology.
→ High-impact, up-to-date review; strong source for EBV lifecycle, immune interaction, latency, and current therapeutic/vaccine strategies.
https://www.nature.com/articles/s41579-025-01181-y Behind paywall:
Tracy, et al. 2012. Persistence of Epstein-Barr virus in self-reactive memory B cells. J Virol.
→ Seminal conceptual review; foundational for understanding how EBV persists by exploiting normal B cell biology—particularly its establishment in long-lived memory B cells and the idea of persistence as a dynamic equilibrium with immune control.
Cohen. 2020. Herpesvirus latency. J Clin Invest.
→ Authoritative review on latency mechanisms; particularly useful for explaining latency as an active, regulated state rather than dormancy.
Silva, et al. 2024. Epstein-Barr virus: the mastermind of immune chaos. Front. Immunol.
→ Broad immunology-focused review; good for immune evasion, modulation, and links to autoimmune processes (e.g., molecular mimicry concepts).
Lyu, et al. 2025. EBV Latency Programs: Molecular and Epigenetic Regulation and Its Role in Disease Pathogenesis. Journal of Medical Virology.
→ Detailed molecular review; strong for explaining different latency programs and how EBV shifts gene expression states over time.
Chen, et al. 2026. EBV strain interacts with host HLA to drive nasopharyngeal carcinoma risk. Nature.
→ Cutting-edge research study; excellent for host–virus interaction framing, especially how viral strain + human genetics jointly influence disease risk.
Chhan, et al. 2026. Transgenic mouse-derived human monoclonal antibodies targeting EBV gp350 and gp42 provide basis for therapeutic development. Cell Reports Medicine.
→ Experimental therapeutic study; key source for entry inhibition, antibody-based prevention strategies, and vaccine-relevant targets (gp350, gp42).